ArticleJournal of gastric cancer2025
Distinct Immunosuppressive Tumor Microenvironment in Gastric Cancer With Peritoneal Metastasis.
Article in Journal of gastric cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Higher TIGIT expression in the intraperitoneal immune microenvironment is associated with shorter progression-free survival in patients with gastric cancer with peritoneal metastasis treated with intraperitoneal paclitaxel.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Tumor microenvironment and gut microbiome in immunotherapy resistance in gastric cancer: clinical questions, biological mechanisms, and evidence-based therapeutic perspectives.Medical oncology (Northwood, London, England) · 2026Review
- Catheter based intraperitoneal chemotherapy using taxane for peritoneal metastases from gastric cancer: from bench to bedside-a narrative review.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- Article
- Hydrogel co-delivery of 5-fluorouracil and siRNA attenuates TGF-β1-mediated MMT to prevent postoperative peritoneal metastasis and adhesion in colorectal cancer.Asian journal of pharmaceutical sciences · 2026Article
- Review
- Review
- Review
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight.International journal of molecular sciences · 2026Review
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Immune-related biomarkers in liquid biopsy for cancer: emerging tools for non-invasive precision oncology.Frontiers in cell and developmental biology · 2026Review
- Intraperitoneal immune microenvironment and efficacy of intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastasis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeImmunotherapy combined with chemotherapy is the standard palliative treatment for gastric cancer. However, peritoneal metastases are often resistant to immunotherapy, underscoring the need to better understand the tumor immune microenvironment (TIME). In this study, we aimed to comprehensively analyze the TIME in peritoneal metastases of gastric cancer. MATERIALS AND
methodsPaired single-cell suspensions from malignant ascites and peripheral blood mononuclear cells (PBMCs) were obtained from 27 patients with gastric cancer for multicolor fluorescence-activated cell sorting (FACS) analysis. Cell-free fluids from malignant ascites and plasma of 15 patients with gastric cancer, along with benign ascites from 15 patients with liver cirrhosis, were analyzed using multiplex enzyme-linked immunosorbent assay (ELISA). Paired samples of primary gastric tumors and metastatic peritoneal tumors from 12 patients were evaluated using multiplex immunohistochemistry (IHC).
resultsFACS analysis revealed that T cells in malignant ascites expressed higher levels of immune checkpoint receptors (programmed death-1, T-cell immunoglobulin and mucin-domain containing-3, T-cell immunoglobulin and ITIM domain, lymphocyte activation gene-3, and cytotoxic T-lymphocyte antigen 4), and that CD8⁺ T cells exhibited terminal exhaustion (Eomes
conclusionsOur results revealed distinct peritoneal immunosuppressive TIMEs in patients with gastric cancer with peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.